Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
04:05pm, Wednesday, 01'st Jun 2022
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will par
Expert Ratings for Apellis Pharmaceuticals
09:29pm, Tuesday, 24'th May 2022 Benzinga
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with underst
Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
04:09pm, Tuesday, 24'th May 2022 Benzinga
Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00.
Shares of Apellis Pharmaceuticals are trading down 2.3%
Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
03:05pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:23pm, Friday, 06'th May 2022 GlobeNewswire Inc.
WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
01:55pm, Friday, 06'th May 2022 Zacks Investment Research
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
11:20am, Friday, 06'th May 2022
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
08:05pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pre
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
04:05pm, Thursday, 05'th May 2022
WALTHAM, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pres
Expert Ratings for Apellis Pharmaceuticals
02:05pm, Thursday, 05'th May 2022 Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
1
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
10:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call Transcript
09:05pm, Wednesday, 04'th May 2022
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Meredith Kaya - SVP, IR & Strategic Finance Adam Townsend - Chief Commercial O
Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
08:05pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2022 fi
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
07:30pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced detailed, longer-term da
Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
07:00am, Tuesday, 26'th Apr 2022
WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will
